Podcast
MSL Talk: Tom Caravela, Hahn-Ey Lee
Insight about INSIGHTS, and how they can help your MSL career!
Summary
In this episode, Joe Liberman shares his journey from MSL to Associate Director, offering valuable advice on transitioning roles within medical affairs. He delves into the role of an Insights Lead, emphasizing the significance of MSL insights and how to effectively gather and report them. Joe discusses the impact of insights on MSL performance evaluation and provides year-end performance advice. The conversation shifts to the influence of digital tools on field medical, adaptation strategies, and the future of MSL interactions in a hybrid model. Joe concludes with reflections on the evolving role of MSLs with emerging technologies, expressing gratitude and appreciation.
Joe Liberman, Associate Director, Medical Affairs at UniQure discusses MSL insights and how they can help your career.
Joe shares…
👉 What makes a good MSL Insight and why they are so important
👉 How to effectively go about gathering Insights
👉 Best practices for reporting insights
👉 Advice on how to find success and improve performance
👉 What MSL can expect for 2022
MSL insights, medical affairs career, digital tools in field medical, hybrid MSL interactions, evolving MSL role
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Hahn-Ey Lee
Podcast
MSL Talk: Tom Caravela
A Trip Around the MSL Insights Cycle
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary